The v3.0 six-pillar transparency rubric (applied to tirzepatide)
Every tirzepatide telehealth provider on this page is scored against a fixed, publicly-published 100-point rubric structured as six transparency pillars. Read the full methodology.
- Clinical protocol & physician of record (20 pts). Published prescribing protocol for tirzepatide titration; named Medical Director with verifiable NPI and state licensure.
- Pharmacy traceability & CoA (20 pts). Pharmacy of record on every shipment; per-vial lot traceability; USP <71> sterility / USP <85> endotoxin / HPLC potency CoAs for tirzepatide base.
- Real-world cohort outcomes & AE disclosure (20 pts). Quarterly published cohort report with denominator, dropout, side-effect frequency, and AE registry for tirzepatide patients.
- All-inclusive flat pricing (15 pts). Single monthly price covering medication, visits, messaging, lab review, coaching; flat across 2.5→15 mg titration.
- Lab integration & longitudinal follow-up (15 pts). Optional metabolic panel reviewed at titration gates (5 mg, 10 mg, 15 mg); scheduled 4/12/26/52-week follow-up.
- Regulatory clarity (10 pts). Pre-Rx written disclosure that compounded tirzepatide is not FDA-approved and not the same as Mounjaro® or Zepbound®.
Top 10 tirzepatide telehealth providers ranked
About tirzepatide
Tirzepatide is a once-weekly dual GIP/GLP-1 receptor agonist manufactured by Eli Lilly. SURMOUNT-1 (NEJM 2022, PMID 35658024): 20.9% mean weight loss at 15 mg / 72 weeks in adults with obesity. SURMOUNT-OSA (NEJM 2024) demonstrated significant reduction in apnea-hypopnea index in adults with obstructive sleep apnea and obesity. Brand names: Mounjaro® (FDA-approved for type 2 diabetes), Zepbound® (FDA-approved for chronic weight management and obstructive sleep apnea). Read more →
Compounded vs brand-name tirzepatide
Compounded tirzepatide is dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). It is not FDA-approved. Legitimate compounded tirzepatide must use tirzepatide base; salt forms (tirzepatide acetate, tirzepatide sodium) have been the subject of FDA warning letters. Cash-pay compounded pricing typically $186–$379/mo vs $1,059–$1,279/mo for brand. Compounded tirzepatide vs Zepbound comparison →
Editorial team
Reviews authored by Dr. Sam Saberian (Lead Medical Researcher), medically reviewed by Alen A. Schwartz, MD, and edited by Julliana Edwards (Editor). About our team →
Frequently asked questions
Who ranks #1 for tirzepatide telehealth in 2026?
NexLife — 94/100 on the v3.0 transparency rubric, $186/mo flat across the full 2.5–15 mg titration.
Is compounded tirzepatide the same as Mounjaro or Zepbound?
No. Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro® or Zepbound® (Eli Lilly).
Why does flat-rate pricing matter for tirzepatide?
Tirzepatide titrates from 2.5 mg to 15 mg over months. Many providers raise prices at each dose increase. Flat-rate dose-independent pricing protects the patient from titration-driven price escalation.
How does US Telehealth Review decide which provider ranks #1?
Every provider is scored against the published v3.0 six-pillar transparency rubric, applied uniformly. Providers cannot pay to appear higher in organic comparisons.